---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-032021"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2023-09-12T23:59:59+00:00"
generated_at: "2026-06-10T21:00:26.883859+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Avalo sells 800 series assets to AUG for $150K upfront, up to $45M in milestones

## Summary
- Upfront payment of $150,000 plus potential $45M in milestone payments if first FDA approval for non-rare pediatric indication.
- AUG assumes up to $150K of liabilities and all costs from transaction date; closing expected Q4 2023.
- CEO says divestiture refocuses on immunology assets, improves cash flow and reduces resource utilization on non-core.
- Contingent payments of up to 20% of proceeds from any sale of priority review voucher granted by FDA.

## SEC filing metadata
- accession: 0001628280-23-032021
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2023-09-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828023032021/0001628280-23-032021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828023032021/avtx-20230911.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-032021
- JSON: https://secwatch.observer/filing/0001628280-23-032021.json
- Plain text: https://secwatch.observer/filing/0001628280-23-032021.txt

## Key facts
- Material Agreements
  Avalo Therapeutics, Inc. entered into Asset Purchase Agreement with AUG Therapeutics, LLC valued at an upfront payment of $150,000 (effective 2023-09-11).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: AUG Therapeutics, LLC
  - Value: an upfront payment of $150,000
  - Effective: 2023-09-11
  source text: On September 11, 2023, Avalo Therapeutics, Inc. (the " Company ") entered into an Asset Purchase Agreement (the " Purchase Agreement ") with AUG Therapeutics, LLC
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828023032021/0001628280-23-032021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.